179 related articles for article (PubMed ID: 36943390)
1. Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source.
Ovejero D; Michel Z; Cataisson C; Saikali A; Galisteo R; Yuspa SH; Collins MT; de Castro LF
J Clin Invest; 2023 May; 133(9):. PubMed ID: 36943390
[TBL] [Abstract][Full Text] [Related]
2. Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.
Lim YH; Ovejero D; Sugarman JS; Deklotz CM; Maruri A; Eichenfield LF; Kelley PK; Jüppner H; Gottschalk M; Tifft CJ; Gafni RI; Boyce AM; Cowen EW; Bhattacharyya N; Guthrie LC; Gahl WA; Golas G; Loring EC; Overton JD; Mane SM; Lifton RP; Levy ML; Collins MT; Choate KA
Hum Mol Genet; 2014 Jan; 23(2):397-407. PubMed ID: 24006476
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment.
Ovejero D; Lim YH; Boyce AM; Gafni RI; McCarthy E; Nguyen TA; Eichenfield LF; DeKlotz CM; Guthrie LC; Tosi LL; Thornton PS; Choate KA; Collins MT
Osteoporos Int; 2016 Dec; 27(12):3615-3626. PubMed ID: 27497815
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.
Lim YH; Ovejero D; Derrick KM; ; Collins MT; Choate KA
J Am Acad Dermatol; 2016 Aug; 75(2):420-7. PubMed ID: 27444071
[TBL] [Abstract][Full Text] [Related]
5. Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23.
Avitan-Hersh E; Tatur S; Indelman M; Gepstein V; Shreter R; Hershkovitz D; Brick R; Bergman R; Tiosano D
J Clin Endocrinol Metab; 2014 Jan; 99(1):E132-6. PubMed ID: 24243633
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome.
Sugarman J; Maruri A; Hamilton DJ; Tabatabai L; Luca D; Cimms T; Krolczyk S; Roberts MS; Carpenter TO
Bone; 2023 Jan; 166():116598. PubMed ID: 36341949
[TBL] [Abstract][Full Text] [Related]
7. Keratinocytic epidermal nevi associated with localized fibro-osseous lesions without hypophosphatemia.
Mestach L; Polubothu S; Calder A; Denayer E; Gholam K; Legius E; Levtchenko E; Van Laethem A; Brems H; Kinsler VA; Morren MA
Pediatr Dermatol; 2020 Sep; 37(5):890-895. PubMed ID: 32662096
[TBL] [Abstract][Full Text] [Related]
8. DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.
de Castro LF; Ovejero D; Boyce AM
Eur J Endocrinol; 2020 May; 182(5):R83-R99. PubMed ID: 32069220
[TBL] [Abstract][Full Text] [Related]
9. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous Skeletal Hypophosphatemia Syndrome in Association with a Mosaic
Park PG; Park E; Hyun HS; Kang HG; Ha IS; Cho TJ; Ko JM; Cheong HI
Ann Clin Lab Sci; 2018 Sep; 48(5):665-669. PubMed ID: 30373874
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome.
Carli D; Cardaropoli S; Tessaris D; Coppo P; La Selva R; Cesario C; Lepri FR; Pullano V; Palumbo M; Ramenghi U; Brusco A; Medico E; De Sanctis L; Ferrero GB; Mussa A
Genes Chromosomes Cancer; 2022 Dec; 61(12):740-746. PubMed ID: 35999193
[TBL] [Abstract][Full Text] [Related]
12. Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report.
Khadora M; Mughal MZ
Bone Rep; 2021 Dec; 15():101138. PubMed ID: 34660853
[TBL] [Abstract][Full Text] [Related]
13. Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
Xiao Z; Huang J; Cao L; Liang Y; Han X; Quarles LD
PLoS One; 2014; 9(8):e104154. PubMed ID: 25089825
[TBL] [Abstract][Full Text] [Related]
14. Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome.
Abebe L; Phung K; Robinson ME; Waldner R; Carsen S; Smit K; Tice A; Lazier J; Armour C; Page M; Dover S; Rauch F; Koujok K; Ward LM
Bone Rep; 2024 Mar; 20():101725. PubMed ID: 38229908
[TBL] [Abstract][Full Text] [Related]
15. A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets.
Huynh C; Gillis A; Fazendin J; Abdullatif H
Bone Rep; 2022 Dec; 17():101605. PubMed ID: 35899095
[TBL] [Abstract][Full Text] [Related]
16. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
Ichikawa S; Austin AM; Gray AK; Econs MJ
J Bone Miner Res; 2012 Feb; 27(2):453-60. PubMed ID: 22006791
[TBL] [Abstract][Full Text] [Related]
17. HRAS-related epidermal nevus syndromes: Expansion of the spectrum with first branchial arch defects.
Beyens A; Lietaer C; Claes K; De Baere E; Goeteyn M; Lerut B; Syryn H; Vanakker O; Van der Meulen J; Vanwalleghem L; Callewaert B
Clin Genet; 2023 Jun; 103(6):709-713. PubMed ID: 36896710
[TBL] [Abstract][Full Text] [Related]
18. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
[TBL] [Abstract][Full Text] [Related]
19. FGF23 and its role in X-linked hypophosphatemia-related morbidity.
Beck-Nielsen SS; Mughal Z; Haffner D; Nilsson O; Levtchenko E; Ariceta G; de Lucas Collantes C; Schnabel D; Jandhyala R; Mäkitie O
Orphanet J Rare Dis; 2019 Feb; 14(1):58. PubMed ID: 30808384
[TBL] [Abstract][Full Text] [Related]
20. FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6.
Uchihashi K; Nakatani T; Goetz R; Mohammadi M; He X; Razzaque MS
Contrib Nephrol; 2013; 180():124-37. PubMed ID: 23652555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
